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cost-effective situation was maintained in all sensitivity analyses. In deterministic 
analysis, the results were most sensitive to differences in index hospitalisation length 
of stay between strategies and proportional GPI utilisation (eptiﬁbatide/abciximab). 
In probabilistic analysis, 95.6% of samples (9,557 of 10,000) indicated a dominant 
situation. CONCLUSIONS: The use of bivalirudin instead of heparin plus GPI 
is dominant, i.e. clinically advantageous and cost-saving, in STEMI patients planned 
for PPCI, when UK valuations are applied to the HORIZONS study.
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OBJECTIVES: Pulmonary Arterial Hypertension (PAH) is a devastating disease, 
which has a signiﬁcant impact on patients’ quality of life and mortality. Both bosentan 
and inhaled iloprost (INHI) have demonstrated prolonged survival in long-term obser-
vational studies. We assessed the cost-effectiveness of adding bosentan, INHI or no 
active treatment (NAT) to palliative care, for patients with PAH of functional class 
(FC) III in Finland. METHODS: A cost-utility model simulated hypothetical patients 
with PAH, using a lifetime horizon and considering only direct medical costs. Patients 
were assumed to either remain in their FC at 12 weeks until death or to deteriorate 
to FC IV and then receive INHI and palliative care until death. It was assumed that 
the initial choice of treatment would not affect survival, but instead would affect the 
proportion of time spent in FC IV. Deterioration was approximated by time to clinical 
worsening (TTCW), a composite measure of death or worsening of PAH leading to a 
change in treatment. Data on TTCW was taken from published literature and hospital 
databases containing over three years of data for bosentan and from published litera-
ture for palliative care alone. For INHI, the TTCW was favourably assumed to equal 
that for bosentan. The utility associated with each FC taken from published literature; 
non-drug costs were estimated based on published literature and veriﬁed by a Finnish 
expert clinician. Costs and beneﬁts were discounted at 3% per annum. RESULTS: 
Bosentan dominated INHI, providing equivalent QALYs at a reduced cost. Bosentan 
also dominated NAT, providing an additional 0.38 QALYs whilst saving a8.142. 
Probabilistic sensitivity analyses estimated the probabilities of bosentan being cost-
effective compared with NAT as 79% and 86% at cost per QALY thresholds of 
a30,000 and a50,000 respectively. CONCLUSIONS: Bosentan is a more cost-effective 
ﬁrst-line therapy for patients with PAH FC III in Finland than either INHI or NAT.
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OBJECTIVES: Primary Pulmonary Hypertension (PPH) is a rare, progressive degen-
erative disorder resulting in deteriorating functional status, poor quality of life and 
ultimately death. Inhaled iloprost is indicated for the treatment of patients with PPH 
at New York Heart Association (NYHA) functional class III. This study used an eco-
nomic model to evaluate the cost-effectiveness of inhaled iloprost compared to current 
standard treatment in PPH. METHODS: A Markov model was used to allocate 
patients to states according to NYHA functional classiﬁcation and treatment received. 
Patients enter the model when oral therapies have failed or not been tolerated and can 
improve NYHA classiﬁcation, remain stable, deteriorate or die. The model compares 
i) inhaled iloprost until patients reach NYHA IV; then, intravenous epoprostenol with 
ii) immediate epoprostenol. Efﬁcacy was taken from 12 week placebo controlled 
studies of each agent; quality of life from EQ-5D data collected in the study of iloprost. 
Costs were estimated at 2008 prices from the perspective of the NHS. The time horizon 
of the economic analysis is from failure of oral therapy until death; the primary 
outcome is cost per QALY gained. RESULTS: The model estimated that treating with 
inhaled iloprost will reduce lifetime cost by £348,000 (95% CI: £223,000, £529,000) 
and increase QALYs by 0.04 (0.92, 0.51) per person treated. The model is sensitive 
to the cost of the drugs used, but less sensitive to the other costs of managing PPH, 
utility inputs or the sources of efﬁcacy and safety inputs chosen. CONCLUSIONS: 
Using inhaled iloprost before epoprostenol offers substantial savings compared to 
immediate epoprostenol, with no signiﬁcant impact on health outcomes. The strategy          
of reserving intravenous therapy for patients unable to tolerate less expensive and 
invasive therapies would be economically attractive.
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OBJECTIVES: To estimate the long- and short-term costs and effects of 2 year treat-
ment with high-dose atorvastatin versus high and standard dose simvastatin in patients 
with acute coronary syndrome (ACS). METHODS: Efﬁcacy is estimated based on a 
Bayesian meta-analysis linking decrease in LDL cholesterol levels to decreases in sec-
ondary cardiac events (MIs, strokes, cardiovascular deaths) drawing data from statin 
trials in ACS (AtoZ, MIRACL, PROVE-IT) and using priors from published statin 
meta analyses (CTT, Law). A Markov model combines estimates of the occurrence of 
later events; Dutch cost data; and quality of life. Risks are taken from the ACS CURE 
study. RESULTS: Analyses are conducted using a baseline event risk during the ﬁrst 
6 months of 12.1% and of 3.89% during later months. A base case analysis of atorv-
astatin 80 mg versus simvastatin 80 mg is chosen to align with clinical trial evidence 
used in the Bayesian analysis. This resulted in a cost per QALY of a29,000 and a 
number needed to treat to avoid one event (NNT) estimate of 80. The comparison of 
atorvastatin 80 mg and simvastatin 40 mg resulted in a NNT of approximately 58 
and a cost per QALY estimate of a21,000, based on the assumption that atorvastatin 
80 mg has an 18% greater efﬁcacy in terms of LDL-C reduction. ICERs improve when 
risk with age is reduced, lower discount rates are used, and when atorvastatin cost is 
decreased. CONCLUSIONS: Based on preliminary ﬁndings, the probability that high-
dose atorvastatin has a cost effectiveness ratio under a30,000 is estimated at 67.3% 
when compared to simvastatin 40 mg and at 56.9% when compared with 80 mg of 
simvastatin. Univariate sensitivity analyses show that changes in the costs of atorvas-
tatin, and the risk of having events have the biggest impact on the results.
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OBJECTIVES: Dronedarone is a new multichannel-blocking antiarrhythmic drug. In 
ATHENA, dronedarone (400 mg bid), reduced cardiovascular hospitalizations or 
death by 24% (p  0.0001) versus standard of care (SOC) alone. Our objective was 
to predict the long-term health effects in terms of survival and quality-adjusted survival 
comparing dronedarone on top of SOC versus SOC alone, amiodarone or sotalol. 
METHODS: A state transition model (evaluated using 1st order Monte Carlo simula-
tion) was developed. When treated with dronedarone or SOC, the risk of suffering 
symptomatic AF, stroke, acute coronary syndromes (ACS), congestive heart failure or 
cardiovascular death, or discontinuing treatment was estimated using survival analysis 
based on the ATHENA patient level data (n  4,628). Death from non-cardiovascular 
causes or following stroke or CHF was based on UK national statistics and literature 
data. Patients treated with amiodarone or sotalol had the risk of events modiﬁed with 
relative risks based on a mixed treatment comparison. When discontinuing dronedar-
one or rhythm control therapy, patients were assumed to receive SOC alone and thus 
have the same transition probabilities as in the SOC arm. Outcomes were discounted 
at 3.5% per annum. RESULTS: Assuming lifetime treatment, the predicted survival 
with dronedarone was 9.01. The corresponding number of QALYs was 6.97. With 
amiodarone, the model predicts an expected survival of 7.14 years (5.52 QALYs). For 
sotalol the corresponding numbers were 5.83 years and 4.53 QALYs. CONCLU-
SIONS: Dronedarone demonstrated longer predicted survival compared to SOC alone, 
amiodarone and sotalol. This beneﬁt is sustained when adjusted by quality of life, and 
is comparable with survival gains from established interventions in cardiology.
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OBJECTIVES: Preliminary evidence indicates that intra-arterial (IA) thrombolysis is 
a more effective treatment for a subgroup of ischemic stroke patients who have a 
visible intracranial occlusion than intravenous (IV) thrombolysis. This cost-utility 
analysis compares four treatment strategies for ischemic stroke: conservative treat-
ment, IV thrombolysis, IA thrombolysis and a bridging strategy of both IV and IA 
thrombolysis (with or without mechanical thrombectomy). METHODS: A health 
economic model was developed that compared the four different treatments. A deci-
sion tree with a Markov model was used to assess 6 months- and lifetime costs (in 
Euros) and effects (in QALYs) of these different treatment strategies. A literature 
search provided the estimates used in the decision tree and data from the EDISSE trial 
was used for cost estimates, combined with cost estimates from Erasmus MC Univer-
sity Hospital Rotterdam on IA thrombolysis. Current Dutch epidemiological informa-
tion was used in the Markov model to calculate lifetime costs and effects for all 
treatment strategies. RESULTS: From a lifetime perspective, IV thrombolysis is the 
dominant treatment strategy: it saves a1717 per QALY gained compared to the con-
servative treatment. The bridging strategy costs an additional a7217 per QALY gained 
compared to IV thrombolysis. IA thrombolysis is dominated by the other strategies 
as it gains equal QALYs as IV thrombolysis while it is a slightly more expensive treat-
ment. A probabilistic sensitivity analysis shows that depending on the willingness to 
pay, these treatment strategies are cost-effective at six months in 84 percent of cases. 
CONCLUSIONS: The bridging strategy signiﬁcantly improves functional outcome of 
acute ischemic stroke patients at reasonable additional costs. However, more empirical 
studies need to be performed in order to reduce the considerable amount of uncertainty 
concerning the costs and effects of IA thrombolysis for acute ischemic stroke.
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OBJECTIVES: The aim of our study was to compare the costs and cost drivers of 
contrast-enhanced magnetic resonance angiography (MRA) and digital subtraction 
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angiography (DSA) when used to diagnose peripheral arterial occlusive disease 
(PAOD) from a German Hospital’s perspective. METHODS: In this study we consid-
ered the direct cost attributable to the radiological department in a hospital, including 
proportionate investigation costs such as personnel and machine usage. The costs for 
contrast agents and consumer goods were considered in a second step as they vary 
strongly from hospital to hospital. A total of eleven examinations, each of MRA and 
DSA type, were documented and analyzed. RESULTS: The investigation costs for a 
MRA examination excluding consumer goods was found to be a142.38 and about 
20% (a34.25) lower than that of a DSA-examination (a176.63), owing to the shorter 
occupation time of the operating room with MRA (average: 32 minutes) than with 
DSA (average: 58 minutes) and resulting in a lower proportional investigation costs 
for machine, room, and personnel per examination assuming routine operating hours 
of 12 hours per day at seven days a week. When the list prices for consumer goods 
were also regarded, there was still an advantage for MRA of a11.22 (^7%) per 
examination. CONCLUSIONS: For patients with suspected PAOD angiography with 
contrast-enhanced MRA was found to be less costly than DSA. Our results align with 
cost-effectiveness analyses conducted in the UK and the USA that included in addition 
the outcomes of diagnosis-based therapeutic decisions. Increased use of contrast-
enhanced MRA for diagnostic purposes and optimization of cost drivers might 
promote cost reductions in radiological departments in German hospitals.
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OBJECTIVES: To determine the health care cost and the labour incapacity of hyper-
tension (AHT) according to different levels of morbidity in primary care setting 
(PC). METHODS: Retrospective-multicentric design. Patients’ q 40 year from seven    
teams of PC (year 2008) were included. Main measures: age, sex, cardiovascular co-
morbidity, Charlson index and general morbidity levels (Adjusted Clinical Groups; 
low, moderate and high). It was established a model of direct costs (differentiating: 
ﬁxed and variable [drugs, tests and referrals]) and indirect. Logistic regression analysis 
and ANCOVA was used for the model correction. Statistical signiﬁcance: P  0.05 
RESULTS: The prevalence of hypertension was 28.4% (95% conﬁdence interval [CI]: 
27.4–29.4%), mean age 67.5 (11.7) years and 56.7% of female. 73.2% of patients 
had moderate co-morbidity (95% CI: 71.3–75.1%). The average/unit of the total cost 
was a1312.1 (range, low co-morbidity: a633.1, moderately: a1297.2 and high: 
a2307.8, P  0.001). Health care cost represented 98.2% of the whole and medication           
69.4%. Morbidity with high cardiovascular event (OR  3.5), smoking (OR  1.4) 
and obesity (OR  1.3), P  0.02 was associated. The correlation of the health cost 
and total cost with the episodes number was 51.4% and 50.6% respectively, P  
0.001. CONCLUSIONS: Patients with AHT have a high health care cost, mainly in 
pharmacy. The total costs increase with age and level of general morbidity. The AHT 
should be considered in conjunction with other cardiovascular risk factors. The cost 
in work labour incapacity is low.
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OBJECTIVES: To assess direct in-hospital costs of CABG in patients hospitalized with 
acute heart failure (AHF) from health care payer perspective and to analyze the burden 
of CABG procedure in total in-hospital cost of AHF. METHODS: From total 1357 
patients hospitalized with AHF in University Hospital Brno (UH) between 2005 and 
2007, 4.6% patients were sent to undergo CABG procedure at the Cardio-surgical 
Centre. Direct cost (include ﬂat rate of admission, stay, medication and service) associ-
ated with contiguous AHF hospitalisation and cost of consecutive CABG were evalu-
ated together as well as separately. (1a  28.63CZK). RESULTS: Forty-six patients  
with de-novo AHF and 17 patients with acute decompensation of chronic heart failure 
were analysed (79.4% male; mean age 68.3 years; 38.7% after myocardial infarction). 
The median length-of-stay (LOS) in both centres was 25 days, mean cost a11953. 
Both LOS (median 23.5; 23.5 and 31 days) and costs (mean a 8855; a10,915; a16,742) 
increased over the years 2005–2007 (statistical signiﬁcant difference in in-hospital 
costs p  0.006, Kruskal-Wallis test). 5 patients stayed in intensive care unit (ICU) 
with median LOS 20 days and mean cost a25,928, others spent median 10 days in 
ICU and 16 days in standard cardiology unit with mean cost a10748. Stay in UH 
Brno formed 9.2% total costs (median LOS 11 days; mean a1,098; PCI performed in 
7.9% patients); the remainder was concerned with CABG procedure (mean a10,855; 
LOS 15 days). Two patients (3.2%) died after CABG. CONCLUSIONS: Acute heart 
failure is a life threatening disease which includes variable causes and complications. 
One of the most costly procedures in AHF patients is revascularisation by means of 
percutaneous coronary intervention or CABG. CABG made 15.3% of total in-hospital 
costs although it was carried out in less than 5% patients.
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OBJECTIVES: Hyponatremia has been associated with risks of in-hospital complica-
tions and mortality in patients with heart failure (HF). However, the nature of the 
relationship between serum sodium (Na) and length of stay in the setting of contem-
porary HF treatment strategies is not known. We evaluated the impact of hyponatre-
mia on LOS from the multinational EVEREST (Efﬁcacy of Vasopressin Antagonism    
in Heart Failure: Outcome Study with Tolvaptan) trial in patients hospitalized with 
HF. METHODS: In the standard of care (SOC) arm of EVEREST, initial LOS 
of normonatremic patients (q135 mEq/L) was compared to hyponatremic patients 
(135 mEq/L, 130 mEq/L, respectively) to assess the association between Na and 
overall LOS. Bivariate analysis was performed producing unadjusted mean LOS dif-
ferences between normatremic and hyponatremic patient cohorts. An analysis of 
covariance (ANCOVA) model was employed to account for potential regional varia-
tion in care delivery. The model was adjusted for hyponatremia status as a factor 
and both region and hyponatremia status and region interaction as covariates. 
Signiﬁcance was assessed with student’s t-test at (p  0.05). RESULTS: Patients with 
admission Na  135 mEq/L (N  216) had an adjusted LOS 3.06 (SE  .533) days 
longer than patients Na q 135 mEq/L (N    1798)(p  0.001). More severely hypona-
tremic patients (130 mEq/L)(N  48) had an adjusted LOS 4.91 (SE  1.16) days 
longer than those with an admission Na q 135 mEq/L (N    1957)(p  0.001). The 
magnitude and direction of the association between hyponatremia and LOS was con-
sistent in both the bivariate and multivariate analyses. These ﬁndings were also con-
ﬁrmed in the limited subset of U.S. patients: hyponatremia (n  68)(135 mEq/L) was 
associated with a LOS 1.39 days longer than normonatremia (n  489)(q135 mEq/L) 
(p  0.05). CONCLUSIONS: Hyponatremia in patients hospitalized for heart failure 
is associated with a statistically signiﬁcant longer LOS as compared with normona-
tremic patients. Further evaluation of the economic burden of this comorbidity is 
warranted.
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OBJECTIVES: Readmission within 30 days of discharge following an acute myocar-
dial infarction (AMI) has been adopted as a quality indicator for US hospitals. 
Whether speciﬁc therapeutic interventions lead to reductions in readmissions is 
unknown. METHODS: We compared rates of readmission within 30 days, and associ-
ated hospitalization costs in patients who were originally admitted for acute coronary 
syndromes (ACS) with planned PCI, and treated with prasugrel vs. clopidogrel in 
the TRITON-TIMI 38 Trial. Patients with a history of stroke/TIA were excluded. 
Data for rehospitalizations were collected for patients from 8 pre-speciﬁed countries 
(U.S.,Australia,Canada,Germany,Italy,Spain,UK,France; n  3233 prasugrel, n  3215 
clopidogrel). Diagnosis Related Groups (DRGs) were used to classify type of hospi-
talization, to which average 2005 Medicare reimbursement rates were applied. Rehos-
pitalization rates were compared between groups using Poisson regression. RESULTS: 
There was a reduction in the 30-day rate of rehospitalization for revascularization 
(PCI or CABG) with prasugrel vs. clopidogrel (4.33 vs. 5.69 per 100 patients, p  
0.015) as well as for PCI (3.80 vs. 4.95 per 100 patients, p  0.03). The reduction in 
PCI rehospitalizations was primarily among patients with both PCI and AMI (0.31 
vs. 1.06, p  0.0006). For patients with an index ST-elevation MI, there was a signiﬁ-
cant reduction in PCI rehospitalizations in the setting of an MI (0.28 vs. 1.46, p  
0.034). The overall 30-day rehospitalization rate did not differ signiﬁcantly (9.6 pra-
sugrel vs. 10.8 clopidogrel, per 100 patients, p  0.14) though total 30-day rehospi-
talization costs were lower for prasugrel ($1145 vs. $1419; difference  $274, 95% 
CI: $525, $28). The difference in costs due to PCI-related rehospitalizations was 
$214 ($387,49). CONCLUSIONS: For ACS patients with no history of stroke/TIA 
and planned PCI, treatment with prasugrel vs. clopidogrel is associated with a lower 
rate of rehospitalization for revascularization–primarily PCI in the setting of MI, and 
concomitant cost savings. These results may be useful in establishing patient manage-
ment strategies in the current quality and reimbursement environment.
